Premium
A novel multi‐epitope vaccine from MMSA ‐1 and DKK 1 for multiple myeloma immunotherapy
Author(s) -
Lu Chenyang,
Meng Shan,
Jin Yanxia,
Zhang Wanggang,
Li Zongfang,
Wang Fang,
WangJohanning Feng,
Wei Yongchang,
Liu Hailing,
Tu Honglei,
Su Dan,
He Aili,
Cao Xingmei,
Zhou Fuling
Publication year - 2017
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14686
Subject(s) - epitope , ctl* , cytotoxic t cell , antigen , virology , immunotherapy , immune system , peptide vaccine , biology , cd8 , immunology , in vitro , biochemistry
Summary The identification of novel tumour‐associated antigens is urgently needed to improve the efficacy of immunotherapy for multiple myeloma ( MM ). In this study, we identified a membrane protein MMSA ‐1 (multiple myeloma special antigen‐1) that was specifically expressed in MM and exhibited significantly positive correlation with MM . We then identified HLA ‐A*0201‐restricted MMSA ‐1 epitopes and tested their cytotoxic T lymphocyte ( CTL ) response. The MMSA ‐1 epitope SLSLLTIYV vaccine was shown to induce an obvious CTL response in vitro . To improve the immunotherapy, we constructed a multi‐epitope peptide vaccine by combining epitopes derived from MMSA ‐1 and Dickkopf‐1 ( DKK 1). The effector T cells induced by multi‐epitope peptide vaccine‐loaded dendritic cells lysed U266 cells more effectively than MMSA ‐1/ DKK 1 single‐epitope vaccine. In myeloma‐bearing severe combined immunodeficient mice, the multi‐epitope vaccine improved the survival rate significantly compared with single‐epitope vaccine. Consistently, multi‐epitope vaccine decreased the tumour volume greatly and alleviated bone destruction. The frequencies of CD 4 + and CD 8 + T cells was significantly increased in mouse blood induced by the multi‐epitope vaccine, indicating that it inhibits myeloma growth by changing T cell subsets and alleviating immune paralysis. This study identified a novel peptide from MMSA ‐1 and the multi‐epitope vaccine will be used to establish appropriate individualized therapy for MM .